Oskuei SR, et al. Design, synthesis and biological evaluation of novel imidazole-chalcone derivatives as potential anticancer agents and tubulin polymerization inhibitors. Bioorg Chem. 2021;112:104904.

Article  Google Scholar 

Emens LA, et al. Challenges and opportunities in cancer immunotherapy: A society for immunotherapy of Cancer (SITC) strategic vision. J Immunother Cancer. 2024;12(6):e009063.

Article  PubMed  PubMed Central  Google Scholar 

Guda R, et al. EGFR, HER2 target based molecular docking analysis, in vitro screening of 2, 4, 5-trisubstituted imidazole derivatives as potential anti-oxidant and cytotoxic agents. J Photochem Photobiol, B. 2017;176:69–80.

Article  CAS  PubMed  Google Scholar 

Labib MB, et al. Azole-hydrazone derivatives: Design, synthesis, in vitro biological evaluation, dual EGFR/HER2 inhibitory activity, cell cycle analysis and molecular docking study as anticancer agents. Bioorg Chem. 2018;76:67–80.

Article  CAS  PubMed  Google Scholar 

Alghamdi EM, et al. Anticancer activities of tetrasubstituted imidazole-pyrimidine-sulfonamide hybrids as inhibitors of EGFR Mutants. ChemMedChem. 2023;18(8):e202200641.

Article  CAS  PubMed  Google Scholar 

Torre LA, et al. Global cancer incidence and mortality rates and trends—an update. Cancer Epidemiol Biomark Prev. 2016;25(1):16–27.

Article  Google Scholar 

Global cancer burden growing, amidst mounting need for services. 2024, world health organization.

Zhao B, et al. SPAG6 regulates cell proliferation and apoptosis via TGF-β/Smad signal pathway in adult B-cell acute lymphoblastic leukemia. Int J Hematol. 2024;119(2):119–29.

Article  CAS  PubMed  Google Scholar 

Kumar TA, et al. Design, 3D QSAR modeling and docking of TGF-β type I inhibitors to target cancer. Comput Biol Chem. 2018;76:232–44.

Article  Google Scholar 

Braczkowski MJ, et al. Pleiotropic Action of TGF-Beta in Physiological and Pathological Liver Conditions. Biomedicines. 2024;12(4):925.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Kinsella, T., et al., TGF-beta inhibitors, in European patent specification. 2020.

Giarratana AO, et al. TGF-β signaling: critical nexus of fibrogenesis and cancer. J Transl Med. 2024;22(1):594.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Wu M, et al. The roles and regulatory mechanisms of TGF-β and BMP signaling in bone and cartilage development, homeostasis and disease. Cell Res. 2024;34(2):101–23.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Gottumukkala SB, Ganesan TS, Palanisamy A. Comprehensive molecular interaction map of TGFβ induced epithelial to mesenchymal transition in breast cancer. Sys Biol Appl. 2024;10(1):53.

Article  CAS  Google Scholar 

Wang Z, et al. TGFβ1-driven SMAD2/3 phosphorylation and myofibroblast emergence are fully dependent on the TGFβ1 pre-activation of MAPKs and controlled by maternal leucine zipper kinase. Cell Signal. 2024;113:110963.

Article  CAS  PubMed  Google Scholar 

Zhu Z, et al. Serine/Threonine kinase 16 phosphorylates STAT3 and confers a JAK2-Inhibition resistance phenotype in triple-negative breast cancer. Biochem Pharmacol. 2024;225:116268.

Article  CAS  PubMed  Google Scholar 

Siljamäki E, et al. Inhibition of TGF-β signaling, invasion, and growth of cutaneous squamous cell carcinoma by PLX8394. Oncogene. 2023;42(49):3633–47.

Article  PubMed  PubMed Central  Google Scholar 

Noshita S, et al. A TGF-β-responsive enhancer regulates SRC expression and epithelial–mesenchymal transition-associated cell migration. J Cell Sci. 2023. https://doi.org/10.1242/jcs.261001.

Article  PubMed  PubMed Central  Google Scholar 

Hotamisligil GS, Davis RJ. Cell signaling and stress responses. Cold Spring Harb Perspect Biol. 2016;8(10):a006072.

Article  PubMed  PubMed Central  Google Scholar 

Guerra A, et al. Combination of a TGF-β ligand trap (RAP-GRL) and TMPRSS6-ASO is superior for correcting β-thalassemia. Am J Hematol. 2024;99(7):1300–12.

Article  CAS  PubMed  Google Scholar 

Kim B-G, et al. Novel therapies emerging in oncology to target the TGF-β pathway. J Hematol Oncol. 2021;14:1–20.

Article  Google Scholar 

Arncr M. Mirza, S.F., CA (US); Rosemary J. Akhurst, Tiburon,CA (US); ou Li, Dublin, CA (US), Method of increasing the ratio of effector t cells to regulatory t cells in a tumor by administering to a subject a tgf-beta inhibitor and a PID-I antibody, in United States, Editor. 2023. p. 86.

Neuzillet C, et al. Targeting the TGFβ pathway for cancer therapy. Pharmacol Ther. 2015;147:22–31.

Article  CAS  PubMed  Google Scholar 

Stover DG, Bierie B, Moses HL. A delicate balance: TGF-β and the tumor microenvironment. J Cell Biochem. 2007;101(4):851–61.

Article  CAS  PubMed  Google Scholar 

Heldin C-H, Landström M, Moustakas A. Mechanism of TGF-β signaling to growth arrest, apoptosis, and epithelial–mesenchymal transition. Curr Opin Cell Biol. 2009;21(2):166–76.

Article  CAS  PubMed  Google Scholar 

David CJ, Massagué J. Contextual determinants of TGFβ action in development, immunity and cancer. Nat Rev Mol Cell Biol. 2018;19(7):419–35.

Article  CAS  PubMed  PubMed Central  Google Scholar 

García-Hernández L, et al. The p38 MAPK components and modulators as biomarkers and molecular targets in cancer. Int J Mol Sci. 2021;23(1):370.

Article  PubMed  PubMed Central  Google Scholar 

Mao X, et al. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives. Mol Cancer. 2021;20:1–30.

Article  Google Scholar 

Martínez-Limón A, et al. The p38 pathway: from biology to cancer therapy. Int J Mol Sci. 2020;21(6):1913.

Article  PubMed  PubMed Central  Google Scholar 

Xu J, Lamouille S, Derynck R. TGF-β-induced epithelial to mesenchymal transition. Cell Res. 2009;19(2):156–72.

Article  CAS  PubMed  Google Scholar 

Lu C, et al. The role of innate immune cells in the tumor microenvironment and research progress in anti-tumor therapy. Front Immunol. 2023;13:1039260.

Article  PubMed  PubMed Central  Google Scholar 

Popova NV, Jücker M. The functional role of extracellular matrix proteins in cancer. Cancers. 2022;14(1):238.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Ren L-L, et al. Transforming growth factor-β signaling: from tissue fibrosis to therapeutic opportunities. Chem Biol Interact. 2023;369:110289.

Article  CAS  PubMed  Google Scholar 

Wang Q, et al. SMAD proteins in TGF-β signalling pathway in cancer: regulatory mechanisms and clinical applications. Diagnostics. 2023;13(17):2769.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Takahashi K, et al. TGF-β generates a population of cancer cells residing in G1 phase with high motility and metastatic potential via KRTAP2–3. Cell Rep. 2022;40(13):111411.

Article  CAS  PubMed  Google Scholar